董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| C. Ann Merrifield | 女 | Director | 74 | 2.98万美元 | 未持股 | 2025-08-01 |
| Nancy L. Snyderman | 女 | Director | 72 | 未披露 | 未持股 | 2025-08-01 |
| Maria Palasis | 女 | President,Chief Executive Officer,Director and Executive Chairman | 60 | 84.27万美元 | 未持股 | 2025-08-01 |
| W. Bradford Smith | 男 | Director | 69 | 0.24万美元 | 未持股 | 2025-08-01 |
| James R. Tobin | 男 | Lead Independent Director | 80 | 未披露 | 未持股 | 2025-08-01 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Maria Palasis | 女 | President,Chief Executive Officer,Director and Executive Chairman | 60 | 84.27万美元 | 未持股 | 2025-08-01 |
| Jason Cavalier | 男 | Chief Financial Officer and Treasurer | 52 | 未披露 | 未持股 | 2025-08-01 |
董事简历
中英对照 | 中文 | 英文- C. Ann Merrifield
-
C. Ann Merrifield自2014年起担任公司的董事。2012年12月-2014年7月她担任PathoGenetix股份有限公司（PathoGenetix, Inc，一家私人持股的健康技术公司）的总裁和首席执行官，2014年7月她自愿申请Chapter 7破产。在加入PathoGenetix股份有限公司（PathoGenetix, Inc）之前，她在Genzyme公司（Genzyme Corporation，现在被Sanofi S.A（一个多元化，全球生物技术公司）拥有）工作了18年。在Genzyme之前，她目前担任Genzyme Biosurgery的总裁，她领导着生物制剂，治疗设备和组合产品的投资的全球业务战略，先前是Genzyme Genetics的营销副总裁、总经理和总裁，扮演一个发展和塑造诊断业务的重要角色。在加入Genzyme之前，她是Bain and 公司（Bain and Company，一家全球战略咨询公司）的合伙人、Aetna Life & Casualty的投资官。她目前担任InVivo Therapeutics Holdings Corp（一家上市的生物技术公司）的董事，也是MassMutual Premier、Select and MML Series Investment Funds的受托人。她拥有缅因大学（University of Maine）动物学学士学位和教育硕士学位和达特茅斯学院阿摩司商学院（达特茅斯学院阿摩司商学院）工商管理硕士学位。
C. Ann Merrifield,has served as a member of Board since September 2019. Ms. Merrifield has also served as a member of the boards of directors for a portfolio of public and private companies in the life sciences sector, which include InVivo Therapeutics Holdings Corp., from November 2014 until January 2025, and Flexion Therapeutics, Inc., from June 2014 to November 2021 until it was acquired by Pacira BioSciences. From July 2015 to August 2018, she served as a director of Juniper Pharmaceuticals, Inc., a healthcare company, until it was acquired by Catalent, Inc. and from December 2016 to January 2019, she served as a director of Veritas Genetics, Inc. Ms. Merrifield also serves as a Trustee for MassMutual Premier, Select and MML Series Investment Funds, the Huntington Theatre Company, the YMCA of Greater Boston, and the International Institute of New England. From November 2012 to July 2014, Ms. Merrifield served as President, Chief Executive Officer and director of PathoGenetix Inc., a genomics company, which voluntarily filed for Chapter 7 bankruptcy in July 2014. Before that, Ms. Merrifield spent 18 years at Genzyme Corporation, serving in several leadership roles, including President of Genzyme Biosurgery, President of Genzyme Genetics and Senior Vice President, Business Excellence. Ms. Merrifield holds a B.A. in Zoology and a Master of Education from the University of Maine and an M.B.A. from the Tuck School of Business at Dartmouth College. - C. Ann Merrifield自2014年起担任公司的董事。2012年12月-2014年7月她担任PathoGenetix股份有限公司（PathoGenetix, Inc，一家私人持股的健康技术公司）的总裁和首席执行官，2014年7月她自愿申请Chapter 7破产。在加入PathoGenetix股份有限公司（PathoGenetix, Inc）之前，她在Genzyme公司（Genzyme Corporation，现在被Sanofi S.A（一个多元化，全球生物技术公司）拥有）工作了18年。在Genzyme之前，她目前担任Genzyme Biosurgery的总裁，她领导着生物制剂，治疗设备和组合产品的投资的全球业务战略，先前是Genzyme Genetics的营销副总裁、总经理和总裁，扮演一个发展和塑造诊断业务的重要角色。在加入Genzyme之前，她是Bain and 公司（Bain and Company，一家全球战略咨询公司）的合伙人、Aetna Life & Casualty的投资官。她目前担任InVivo Therapeutics Holdings Corp（一家上市的生物技术公司）的董事，也是MassMutual Premier、Select and MML Series Investment Funds的受托人。她拥有缅因大学（University of Maine）动物学学士学位和教育硕士学位和达特茅斯学院阿摩司商学院（达特茅斯学院阿摩司商学院）工商管理硕士学位。
- C. Ann Merrifield,has served as a member of Board since September 2019. Ms. Merrifield has also served as a member of the boards of directors for a portfolio of public and private companies in the life sciences sector, which include InVivo Therapeutics Holdings Corp., from November 2014 until January 2025, and Flexion Therapeutics, Inc., from June 2014 to November 2021 until it was acquired by Pacira BioSciences. From July 2015 to August 2018, she served as a director of Juniper Pharmaceuticals, Inc., a healthcare company, until it was acquired by Catalent, Inc. and from December 2016 to January 2019, she served as a director of Veritas Genetics, Inc. Ms. Merrifield also serves as a Trustee for MassMutual Premier, Select and MML Series Investment Funds, the Huntington Theatre Company, the YMCA of Greater Boston, and the International Institute of New England. From November 2012 to July 2014, Ms. Merrifield served as President, Chief Executive Officer and director of PathoGenetix Inc., a genomics company, which voluntarily filed for Chapter 7 bankruptcy in July 2014. Before that, Ms. Merrifield spent 18 years at Genzyme Corporation, serving in several leadership roles, including President of Genzyme Biosurgery, President of Genzyme Genetics and Senior Vice President, Business Excellence. Ms. Merrifield holds a B.A. in Zoology and a Master of Education from the University of Maine and an M.B.A. from the Tuck School of Business at Dartmouth College.
- Nancy L. Snyderman
-
NancyL.Snyderman是一名委员会认证的耳鼻喉科医生，目前是斯坦福大学全球健康创新中心的咨询教授。她曾担任NBC News的首席医学编辑（2006年至2015年），也曾担任宾夕法尼亚大学（the University of Pennsylvania）的耳鼻喉科临床教授（2003年8月至2015年12月）。从2003年1月到2006年9月，Snyderman博士在强生公司公司（一家公开上市的制药公司）担任公司通讯高级副总裁。她从1994年7月到2003年6月在California Pacific Medical Center担任耳鼻喉科医生，从1987年到2003年5月担任ABC News医学编辑。Snyderman博士是美国外科医学院（American College of Surgeons）的研究员。她目前担任GE&；8217；S HealthyMagination、梦百合改善研究所、韦尔斯利学院奥尔布赖特研究所、匹兹堡大学医学中心眼耳基金会和国家脑膜炎基金会的董事。在Snyderman博士担任美国全国广播公司（NBC）和美国广播公司（ABC）医学记者期间，她获得了艾美奖，爱德华·R·莫罗奖，哥伦比亚大学杜邦奖和格雷西奖。Snyderman博士在内布拉斯加大学（University of Nebraska）的医学院就读，并在匹兹堡大学（University of Pittsburgh）完成儿科和耳鼻喉科住院医师。
Nancy L. Snyderman,is an oncologic surgeon and clinical researcher. She was a consulting professor at Stanford University Center for Innovation in Global Health from July 2019 to July 2022, served as Chief Medical Editor at NBC News from 2006 until 2015 and was a clinical professor of Otolaryngology at the University of Pennsylvania from August 2003 to December 2015. Dr. Snyderman was Senior Vice President Corporate Communications at Johnson & Johnson, a publicly-traded pharmaceutical company, from January 2003 to September 2006. She practiced as an Otolaryngologist at UC San Francisco and the California Pacific Medical Center from July 1994 to June 2003 and acted as Medical Editor for ABC News from 1987 until May 2003. Dr. Snyderman previously served on the board of directors of Future Health ESG Corp., a publicly-traded special purpose acquisition company, from September 2021 to March 2024 and Axonics, Inc., a publicly-traded medical device company, from April 2019 to November 2024. Dr. Snyderman is a Kellogg Fellow, a Fellow in the American College of Surgeons and co-founder of the Stanford University-NBC News Global Media Fellowship. During Dr. Snyderman's tenure as a medical journalist at NBC News and ABC News, she received Emmy Awards, Edward R. Murrow Awards, a Columbia University DuPont Award, and a Gracie Award for her reporting. Dr. Snyderman attended medical school at the University of Nebraska and completed residencies in Pediatrics and Otolaryngology at the University of Pittsburgh. - NancyL.Snyderman是一名委员会认证的耳鼻喉科医生，目前是斯坦福大学全球健康创新中心的咨询教授。她曾担任NBC News的首席医学编辑（2006年至2015年），也曾担任宾夕法尼亚大学（the University of Pennsylvania）的耳鼻喉科临床教授（2003年8月至2015年12月）。从2003年1月到2006年9月，Snyderman博士在强生公司公司（一家公开上市的制药公司）担任公司通讯高级副总裁。她从1994年7月到2003年6月在California Pacific Medical Center担任耳鼻喉科医生，从1987年到2003年5月担任ABC News医学编辑。Snyderman博士是美国外科医学院（American College of Surgeons）的研究员。她目前担任GE&；8217；S HealthyMagination、梦百合改善研究所、韦尔斯利学院奥尔布赖特研究所、匹兹堡大学医学中心眼耳基金会和国家脑膜炎基金会的董事。在Snyderman博士担任美国全国广播公司（NBC）和美国广播公司（ABC）医学记者期间，她获得了艾美奖，爱德华·R·莫罗奖，哥伦比亚大学杜邦奖和格雷西奖。Snyderman博士在内布拉斯加大学（University of Nebraska）的医学院就读，并在匹兹堡大学（University of Pittsburgh）完成儿科和耳鼻喉科住院医师。
- Nancy L. Snyderman,is an oncologic surgeon and clinical researcher. She was a consulting professor at Stanford University Center for Innovation in Global Health from July 2019 to July 2022, served as Chief Medical Editor at NBC News from 2006 until 2015 and was a clinical professor of Otolaryngology at the University of Pennsylvania from August 2003 to December 2015. Dr. Snyderman was Senior Vice President Corporate Communications at Johnson & Johnson, a publicly-traded pharmaceutical company, from January 2003 to September 2006. She practiced as an Otolaryngologist at UC San Francisco and the California Pacific Medical Center from July 1994 to June 2003 and acted as Medical Editor for ABC News from 1987 until May 2003. Dr. Snyderman previously served on the board of directors of Future Health ESG Corp., a publicly-traded special purpose acquisition company, from September 2021 to March 2024 and Axonics, Inc., a publicly-traded medical device company, from April 2019 to November 2024. Dr. Snyderman is a Kellogg Fellow, a Fellow in the American College of Surgeons and co-founder of the Stanford University-NBC News Global Media Fellowship. During Dr. Snyderman's tenure as a medical journalist at NBC News and ABC News, she received Emmy Awards, Edward R. Murrow Awards, a Columbia University DuPont Award, and a Gracie Award for her reporting. Dr. Snyderman attended medical school at the University of Nebraska and completed residencies in Pediatrics and Otolaryngology at the University of Pittsburgh.
- Maria Palasis
-
Maria Palasis，自2025年1月起担任Beta Bionics， Inc.董事会成员。Palasis博士此前于2022年9月至2023年9月担任Beta Bionics， Inc.董事会成员。自2023年9月起担任顾问委员会成员。Palasis博士自2014年12月起担任Lyra Therapeutics Inc.（一家专注于开发慢性鼻窦炎疗法的上市生物技术公司）的总裁兼首席执行官，并于2011年3月至2014年12月担任执行副总裁兼首席技术官。此前，她于2008年9月至2011年3月担任Arsenal Medical， Inc.（一家医疗设备公司）的执行副总裁，并于2014年12月至2018年6月担任Arsenal Medical， Inc.及其分拆公司480 Biomedical的总裁兼首席执行官，并于1995年11月至2008年1月在Boston Scientific Corporation（一家医疗设备公司）担任越来越重要的角色。她自2020年9月起担任PanTher Therapeutics， Inc.（私人控股的生物技术公司）的董事会成员；自2015年1月起担任Lyra Therapeutics的董事会成员。此前，她还曾担任Arsenal Medical， Inc.的董事会成员（2015年至2018年）。Palasis博士在辛辛那提大学获得化学工程学士学位和博士学位。
Maria Palasis,has served as President and Chief Executive Officer and a member of Board of Directors since January 2015. Prior to her role with as President and Chief Executive Officer, Dr. Palasis held positions of increasing responsibility, the most recent of which was Executive Vice President and Chief Technology Officer from 2011 to 2015. Before that, in 2008, Dr. Palasis joined Arsenal Medical, Inc., a biotechnology company, as Executive Vice President and subsequently served as President and Chief Executive Officer and a member of the board of directors of Arsenal Medical from January 2015 to June 2018. Before that, from November 1995 to January 2008, Dr. Palasis was employed with the title of Director at Boston Scientific Corporation, a medical device company, where she managed a portfolio of external biotech and medical device investments and led the development of several combination therapies. Dr. Palasis has also served as a member of the board of directors of Beta Bionics, Inc. since January 2025. Dr. Palasis holds a B.S. and Ph.D. in Chemical Engineering from the University of Cincinnati, and she held a postdoctoral fellowship in molecular biology at the University of Cincinnati School of Medicine. - Maria Palasis，自2025年1月起担任Beta Bionics， Inc.董事会成员。Palasis博士此前于2022年9月至2023年9月担任Beta Bionics， Inc.董事会成员。自2023年9月起担任顾问委员会成员。Palasis博士自2014年12月起担任Lyra Therapeutics Inc.（一家专注于开发慢性鼻窦炎疗法的上市生物技术公司）的总裁兼首席执行官，并于2011年3月至2014年12月担任执行副总裁兼首席技术官。此前，她于2008年9月至2011年3月担任Arsenal Medical， Inc.（一家医疗设备公司）的执行副总裁，并于2014年12月至2018年6月担任Arsenal Medical， Inc.及其分拆公司480 Biomedical的总裁兼首席执行官，并于1995年11月至2008年1月在Boston Scientific Corporation（一家医疗设备公司）担任越来越重要的角色。她自2020年9月起担任PanTher Therapeutics， Inc.（私人控股的生物技术公司）的董事会成员；自2015年1月起担任Lyra Therapeutics的董事会成员。此前，她还曾担任Arsenal Medical， Inc.的董事会成员（2015年至2018年）。Palasis博士在辛辛那提大学获得化学工程学士学位和博士学位。
- Maria Palasis,has served as President and Chief Executive Officer and a member of Board of Directors since January 2015. Prior to her role with as President and Chief Executive Officer, Dr. Palasis held positions of increasing responsibility, the most recent of which was Executive Vice President and Chief Technology Officer from 2011 to 2015. Before that, in 2008, Dr. Palasis joined Arsenal Medical, Inc., a biotechnology company, as Executive Vice President and subsequently served as President and Chief Executive Officer and a member of the board of directors of Arsenal Medical from January 2015 to June 2018. Before that, from November 1995 to January 2008, Dr. Palasis was employed with the title of Director at Boston Scientific Corporation, a medical device company, where she managed a portfolio of external biotech and medical device investments and led the development of several combination therapies. Dr. Palasis has also served as a member of the board of directors of Beta Bionics, Inc. since January 2025. Dr. Palasis holds a B.S. and Ph.D. in Chemical Engineering from the University of Cincinnati, and she held a postdoctoral fellowship in molecular biology at the University of Cincinnati School of Medicine.
- W. Bradford Smith
-
W.Bradford Smith自2019年11月以来一直担任我们的董事会成员。史密斯先生自2017年4月起担任基因药物公司HomologyMedicines，Inc.的首席财务官兼财务主管，自2017年7月起担任秘书。2014年3月至2017年4月，史密斯先生担任生物制药公司OcularTherapeutix，Inc.的首席财务官。在加入Ocular Therapeutix之前，Smith先生于2008年7月至2014年3月担任医疗设备公司OmniGuide，Inc.的首席财务官。Smith先生拥有塔夫茨大学（Tufts University）的生物学学士学位和新罕布什尔大学（University of New Hampshire）惠特莫尔商学院（Whittemore School of Business and Economics）的工商管理硕士学位。
W. Bradford Smith,has served as a member of Board since November 2019. Since December 2024, Mr. Smith has served as the Chief Financial Officer of Incendia Therapeutics, Inc. From November 2023 to March 2024, Mr. Smith served as a consultant to Homology Medicines, Inc. (NASDAQ: FIXX), where he served as Chief Financial Officer, Chief Business Officer and Treasurer from March 2022 until November 2023, when the company announced it signed a merger agreement with Q32 Bio, Inc. He also served as Homology's Chief Financial Officer and Treasurer from April 2017 to March 2022 and as Secretary from July 2017 to June 2020. From March 2014 to April 2017, Mr. Smith was Chief Financial Officer of Ocular Therapeutix, Inc., a biopharmaceutical company, where he led the company's strategic financings, including an IPO and subsequent follow-on offerings, and completed a development and commercialization deal with a major biopharmaceutical company. Prior to joining Ocular Therapeutix, Mr. Smith served as Chief Financial Officer of OmniGuide, Inc., a medical device company, from July 2008 to March 2014. Since May 2021, Mr. Smith has served on the board of directors of eGenesis, a private gene editing company. Mr. Smith holds a B.S. in Biology from Tufts University and an M.B.A. from the Whittemore School of Business and Economics at the University of New Hampshire. - W.Bradford Smith自2019年11月以来一直担任我们的董事会成员。史密斯先生自2017年4月起担任基因药物公司HomologyMedicines，Inc.的首席财务官兼财务主管，自2017年7月起担任秘书。2014年3月至2017年4月，史密斯先生担任生物制药公司OcularTherapeutix，Inc.的首席财务官。在加入Ocular Therapeutix之前，Smith先生于2008年7月至2014年3月担任医疗设备公司OmniGuide，Inc.的首席财务官。Smith先生拥有塔夫茨大学（Tufts University）的生物学学士学位和新罕布什尔大学（University of New Hampshire）惠特莫尔商学院（Whittemore School of Business and Economics）的工商管理硕士学位。
- W. Bradford Smith,has served as a member of Board since November 2019. Since December 2024, Mr. Smith has served as the Chief Financial Officer of Incendia Therapeutics, Inc. From November 2023 to March 2024, Mr. Smith served as a consultant to Homology Medicines, Inc. (NASDAQ: FIXX), where he served as Chief Financial Officer, Chief Business Officer and Treasurer from March 2022 until November 2023, when the company announced it signed a merger agreement with Q32 Bio, Inc. He also served as Homology's Chief Financial Officer and Treasurer from April 2017 to March 2022 and as Secretary from July 2017 to June 2020. From March 2014 to April 2017, Mr. Smith was Chief Financial Officer of Ocular Therapeutix, Inc., a biopharmaceutical company, where he led the company's strategic financings, including an IPO and subsequent follow-on offerings, and completed a development and commercialization deal with a major biopharmaceutical company. Prior to joining Ocular Therapeutix, Mr. Smith served as Chief Financial Officer of OmniGuide, Inc., a medical device company, from July 2008 to March 2014. Since May 2021, Mr. Smith has served on the board of directors of eGenesis, a private gene editing company. Mr. Smith holds a B.S. in Biology from Tufts University and an M.B.A. from the Whittemore School of Business and Economics at the University of New Hampshire.
- James R. Tobin
-
James R. Tobin，自2011年起担任董事会主席。1999年至2009年，他担任医疗器械公司Boston Scientific Corporation的退休总裁兼首席执行官。在加入Boston Scientific之前，他曾担任Biogen Inc.的总裁兼首席执行官，从1994年到1997年担任其总裁兼首席运营官。在Biogen之前，他在百特国际公司（Baxter International Inc.）工作了22年，从财务分析师晋升为总裁兼首席运营官。他目前担任Corindus Vascular Robotics、Globus Medical Inc.、Oxford Immunotec, Inc.（上市公司）和Resolys Bio， Inc.（私人公司）的董事。他还曾在Curis， Inc.（1995年至2015年）、Medical Simulation Corp（2012年至2018年）、CardioDX, Inc（2014年至2017年）、Chiasma, Inc（2015年至2016年）和Aptus Endosystems， Inc（2011年至2015年）的董事会任职。他持有Harvard College的学士学位和Harvard Business School的工商管理硕士学位。他还曾在美国海军担任中尉。
James R. Tobin, has served as Chairman of board of directors since 2011. Mr. Tobin is the retired President and CEO of Boston Scientific Corporation, a medical device company, where he served from 1999 to 2009. Prior to Boston Scientific, Mr. Tobin was the President and CEO of Biogen Inc., and, from 1994 to 1997 its President and Chief Operating Officer. Before Biogen, Mr. Tobin spent 22 years with Baxter International Inc., rising from Financial Analyst to President and Chief Operating Officer. Mr. Tobin currently serves as a director of Corindus Vascular Robotics, Globus Medical Inc., Oxford Immunotec, Inc., each of which are public companies, and Resolys Bio, Inc., a private company. Mr. Tobin has also served on the boards of Curis, Inc., from 1995 to 2015 Medical Simulation Corp, from 2012 to 2018 CardioDX, Inc., from 2014 to 2017 Chiasma, Inc., from 2015 to 2016 and Aptus Endosystems, Inc. from 2011 to 2015. Mr. Tobin holds an AB from Harvard College and an MBA from Harvard Business School. Mr. Tobin also served to Lieutenant in the U.S. Navy. - James R. Tobin，自2011年起担任董事会主席。1999年至2009年，他担任医疗器械公司Boston Scientific Corporation的退休总裁兼首席执行官。在加入Boston Scientific之前，他曾担任Biogen Inc.的总裁兼首席执行官，从1994年到1997年担任其总裁兼首席运营官。在Biogen之前，他在百特国际公司（Baxter International Inc.）工作了22年，从财务分析师晋升为总裁兼首席运营官。他目前担任Corindus Vascular Robotics、Globus Medical Inc.、Oxford Immunotec, Inc.（上市公司）和Resolys Bio， Inc.（私人公司）的董事。他还曾在Curis， Inc.（1995年至2015年）、Medical Simulation Corp（2012年至2018年）、CardioDX, Inc（2014年至2017年）、Chiasma, Inc（2015年至2016年）和Aptus Endosystems， Inc（2011年至2015年）的董事会任职。他持有Harvard College的学士学位和Harvard Business School的工商管理硕士学位。他还曾在美国海军担任中尉。
- James R. Tobin, has served as Chairman of board of directors since 2011. Mr. Tobin is the retired President and CEO of Boston Scientific Corporation, a medical device company, where he served from 1999 to 2009. Prior to Boston Scientific, Mr. Tobin was the President and CEO of Biogen Inc., and, from 1994 to 1997 its President and Chief Operating Officer. Before Biogen, Mr. Tobin spent 22 years with Baxter International Inc., rising from Financial Analyst to President and Chief Operating Officer. Mr. Tobin currently serves as a director of Corindus Vascular Robotics, Globus Medical Inc., Oxford Immunotec, Inc., each of which are public companies, and Resolys Bio, Inc., a private company. Mr. Tobin has also served on the boards of Curis, Inc., from 1995 to 2015 Medical Simulation Corp, from 2012 to 2018 CardioDX, Inc., from 2014 to 2017 Chiasma, Inc., from 2015 to 2016 and Aptus Endosystems, Inc. from 2011 to 2015. Mr. Tobin holds an AB from Harvard College and an MBA from Harvard Business School. Mr. Tobin also served to Lieutenant in the U.S. Navy.
高管简历
中英对照 | 中文 | 英文- Maria Palasis
Maria Palasis，自2025年1月起担任Beta Bionics， Inc.董事会成员。Palasis博士此前于2022年9月至2023年9月担任Beta Bionics， Inc.董事会成员。自2023年9月起担任顾问委员会成员。Palasis博士自2014年12月起担任Lyra Therapeutics Inc.（一家专注于开发慢性鼻窦炎疗法的上市生物技术公司）的总裁兼首席执行官，并于2011年3月至2014年12月担任执行副总裁兼首席技术官。此前，她于2008年9月至2011年3月担任Arsenal Medical， Inc.（一家医疗设备公司）的执行副总裁，并于2014年12月至2018年6月担任Arsenal Medical， Inc.及其分拆公司480 Biomedical的总裁兼首席执行官，并于1995年11月至2008年1月在Boston Scientific Corporation（一家医疗设备公司）担任越来越重要的角色。她自2020年9月起担任PanTher Therapeutics， Inc.（私人控股的生物技术公司）的董事会成员；自2015年1月起担任Lyra Therapeutics的董事会成员。此前，她还曾担任Arsenal Medical， Inc.的董事会成员（2015年至2018年）。Palasis博士在辛辛那提大学获得化学工程学士学位和博士学位。
Maria Palasis,has served as President and Chief Executive Officer and a member of Board of Directors since January 2015. Prior to her role with as President and Chief Executive Officer, Dr. Palasis held positions of increasing responsibility, the most recent of which was Executive Vice President and Chief Technology Officer from 2011 to 2015. Before that, in 2008, Dr. Palasis joined Arsenal Medical, Inc., a biotechnology company, as Executive Vice President and subsequently served as President and Chief Executive Officer and a member of the board of directors of Arsenal Medical from January 2015 to June 2018. Before that, from November 1995 to January 2008, Dr. Palasis was employed with the title of Director at Boston Scientific Corporation, a medical device company, where she managed a portfolio of external biotech and medical device investments and led the development of several combination therapies. Dr. Palasis has also served as a member of the board of directors of Beta Bionics, Inc. since January 2025. Dr. Palasis holds a B.S. and Ph.D. in Chemical Engineering from the University of Cincinnati, and she held a postdoctoral fellowship in molecular biology at the University of Cincinnati School of Medicine.- Maria Palasis，自2025年1月起担任Beta Bionics， Inc.董事会成员。Palasis博士此前于2022年9月至2023年9月担任Beta Bionics， Inc.董事会成员。自2023年9月起担任顾问委员会成员。Palasis博士自2014年12月起担任Lyra Therapeutics Inc.（一家专注于开发慢性鼻窦炎疗法的上市生物技术公司）的总裁兼首席执行官，并于2011年3月至2014年12月担任执行副总裁兼首席技术官。此前，她于2008年9月至2011年3月担任Arsenal Medical， Inc.（一家医疗设备公司）的执行副总裁，并于2014年12月至2018年6月担任Arsenal Medical， Inc.及其分拆公司480 Biomedical的总裁兼首席执行官，并于1995年11月至2008年1月在Boston Scientific Corporation（一家医疗设备公司）担任越来越重要的角色。她自2020年9月起担任PanTher Therapeutics， Inc.（私人控股的生物技术公司）的董事会成员；自2015年1月起担任Lyra Therapeutics的董事会成员。此前，她还曾担任Arsenal Medical， Inc.的董事会成员（2015年至2018年）。Palasis博士在辛辛那提大学获得化学工程学士学位和博士学位。
- Maria Palasis,has served as President and Chief Executive Officer and a member of Board of Directors since January 2015. Prior to her role with as President and Chief Executive Officer, Dr. Palasis held positions of increasing responsibility, the most recent of which was Executive Vice President and Chief Technology Officer from 2011 to 2015. Before that, in 2008, Dr. Palasis joined Arsenal Medical, Inc., a biotechnology company, as Executive Vice President and subsequently served as President and Chief Executive Officer and a member of the board of directors of Arsenal Medical from January 2015 to June 2018. Before that, from November 1995 to January 2008, Dr. Palasis was employed with the title of Director at Boston Scientific Corporation, a medical device company, where she managed a portfolio of external biotech and medical device investments and led the development of several combination therapies. Dr. Palasis has also served as a member of the board of directors of Beta Bionics, Inc. since January 2025. Dr. Palasis holds a B.S. and Ph.D. in Chemical Engineering from the University of Cincinnati, and she held a postdoctoral fellowship in molecular biology at the University of Cincinnati School of Medicine.
- Jason Cavalier
Jason Cavalier，自2021年9月起担任首席财务官、财务主管。他还在2021年9月至2024年3月期间担任秘书。在加入公司之前，Cavalier先生曾在Cantor Fitzgerald & Co.担任董事总经理和生命科学并购主管，在2017年至2021年期间，他领导了医疗技术、诊断和生物制药领域的交易。在此之前，Cavalier先生曾于2009年至2017年在加拿大皇家银行资本市场有限责任公司担任并购总监，主要专注于就一系列战略咨询任务向高级管理层和董事会提供建议，包括合并、收购、资产剥离和杠杆收购。Cavalier先生还曾在BARCLAYS CAPITAL INC.、贝尔斯登公司和雷曼兄弟公司的投资银行部门担任越来越重要的职务。Cavalier先生获得了康奈尔大学应用经济学和商业管理学士学位以及哥伦比亚大学商学院工商管理硕士学位。
Jason Cavalier,has served as Chief Financial Officer, and Treasurer since September 2021. He also served as Secretary from September 2021 to March 2024. Prior to joining Company, Mr. Cavalier served as a Managing Director and the Head of Life Sciences Mergers and Acquisitions at Cantor Fitzgerald & Co., where he led transactions across the medical technology, diagnostics and biopharma sectors, from 2017 to 2021. Prior to that, Mr. Cavalier served as a Director, Mergers and Acquisitions, at RBC Capital Markets LLC from 2009 to 2017, where he primarily focused on advising senior management and boards of directors on a range of strategic advisory assignments including mergers, acquisitions, divestitures and leveraged buyouts. Mr. Cavalier has also held positions of increasing responsibility within the investment banking divisions of Barclays Capital Inc., Bear Stearns & Co. Inc., and Lehman Brothers Inc. Mr. Cavalier received a B.S. in Applied Economics and Business Management from Cornell University and an M.B.A. from Columbia University Business School.- Jason Cavalier，自2021年9月起担任首席财务官、财务主管。他还在2021年9月至2024年3月期间担任秘书。在加入公司之前，Cavalier先生曾在Cantor Fitzgerald & Co.担任董事总经理和生命科学并购主管，在2017年至2021年期间，他领导了医疗技术、诊断和生物制药领域的交易。在此之前，Cavalier先生曾于2009年至2017年在加拿大皇家银行资本市场有限责任公司担任并购总监，主要专注于就一系列战略咨询任务向高级管理层和董事会提供建议，包括合并、收购、资产剥离和杠杆收购。Cavalier先生还曾在BARCLAYS CAPITAL INC.、贝尔斯登公司和雷曼兄弟公司的投资银行部门担任越来越重要的职务。Cavalier先生获得了康奈尔大学应用经济学和商业管理学士学位以及哥伦比亚大学商学院工商管理硕士学位。
- Jason Cavalier,has served as Chief Financial Officer, and Treasurer since September 2021. He also served as Secretary from September 2021 to March 2024. Prior to joining Company, Mr. Cavalier served as a Managing Director and the Head of Life Sciences Mergers and Acquisitions at Cantor Fitzgerald & Co., where he led transactions across the medical technology, diagnostics and biopharma sectors, from 2017 to 2021. Prior to that, Mr. Cavalier served as a Director, Mergers and Acquisitions, at RBC Capital Markets LLC from 2009 to 2017, where he primarily focused on advising senior management and boards of directors on a range of strategic advisory assignments including mergers, acquisitions, divestitures and leveraged buyouts. Mr. Cavalier has also held positions of increasing responsibility within the investment banking divisions of Barclays Capital Inc., Bear Stearns & Co. Inc., and Lehman Brothers Inc. Mr. Cavalier received a B.S. in Applied Economics and Business Management from Cornell University and an M.B.A. from Columbia University Business School.